AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25446887 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus intravenous (IV) calcifediol (450μg)
Number of subjects: 0
Study 25446887 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral modified-release (MR) calcifediol (450 or 900μg)
Number of subjects: 0
Study 22836514 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g PL/day
Number of subjects: 14
Study 22836514 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g PL/day
Number of subjects: 14
Study 22836514 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g PL/day + 2 g PSt/day
Number of subjects: 14
Study 21185685 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session motivationally focused intervention
Number of subjects: 332
Study 21185685 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only condition
Number of subjects: 332
Study 18316290 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (4 two-hour weekly sessions)
Number of subjects: 57
Study 17080927 — intervention group
Group type: EXPERIMENTAL
Intervention: New candidate therapy for neuropathic pain
Number of subjects: 0
Study 17080927 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14597641 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg aliskiren
Number of subjects: 226
Study 14597641 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg aliskiren
Number of subjects: 226
Study 14597641 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg aliskiren
Number of subjects: 226
Study 14597641 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg aliskiren
Number of subjects: 226
Study 14597641 — intervention group
Group type: COMPARATOR
Intervention: 100 mg losartan
Number of subjects: 226
Study 10811085 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 220
Study 10811085 — intervention group
Group type: COMPARATOR
Intervention: LASIK
Number of subjects: 220
Study 8828996 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 7-10 nights
Number of subjects: 136
Study 8828996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 1433163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium diet (LD)
Number of subjects: 77
Study 1433163 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (UD)
Number of subjects: 77
Study 3976825 — intervention group
Group type: EXPERIMENTAL
Intervention: Design Copying Test (DC)
Number of subjects: 180
Study 3976825 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor Accuracy-Revised Test (MAC-R)
Number of subjects: 180
Study 3976825 — intervention group
Group type: EXPERIMENTAL
Intervention: Japan-born children
Number of subjects: 180
Study 31463952 — intervention group
Group type: COMPARATOR
Intervention: Ceiling fan (30°C, max. 0.8 m/s, mean 0.7 m/s)
Number of subjects: 18
Study 31463952 — intervention group
Group type: EXPERIMENTAL
Intervention: Task fan (30°C, max. 0.8 m/s, mean 0.6 m/s)
Number of subjects: 18
Study 31463952 — intervention group
Group type: COMPARATOR
Intervention: Thermally neutral (27°C, 0.2 m/s)
Number of subjects: 18
Study 30672194 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-time needle retaining at Baihui (GV 20)
Number of subjects: 70
Study 30672194 — intervention group
Group type: COMPARATOR
Intervention: Neurological routine treatment and western medicine rehabilitation therapy (Control)
Number of subjects: 70
Study 26573368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin, mineral and n-3 fatty acid supplementation
Number of subjects: 196
Study 26573368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 24856273 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad-assisted cognitive training
Number of subjects: 20
Study 24856273 — intervention group
Group type: COMPARATOR
Intervention: Control group (without cognitive training)
Number of subjects: 20
Study 22451180 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 52
Study 22451180 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 52
Study 20216069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube S II (LTS II)
Number of subjects: 120
Study 20216069 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube disposable (LTS‐D)
Number of subjects: 120
Study 20216069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach laryngeal mask (Fastrach)
Number of subjects: 120
Study 20216069 — intervention group
Group type: EXPERIMENTAL
Intervention: Fastrach laryngeal mask disposable (Fastrach‐D)
Number of subjects: 120
Study 18521538 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (5-ISMN) 30 mg three times daily for 7 days
Number of subjects: 11
Study 18521538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 16240277 — intervention group
Group type: EXPERIMENTAL
Intervention: Perkins tonometer measurements after LASIK
Number of subjects: 125
Study 16240277 — intervention group
Group type: COMPARATOR
Intervention: Measured IOP at all set pressure levels
Number of subjects: 125
Study 16240277 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction for measured IOP after LASIK
Number of subjects: 125
Study 12123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 30 microg/kg
Number of subjects: 100
Study 12123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 60 microg/kg
Number of subjects: 100
Study 12123336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim 100 microg/kg
Number of subjects: 100
Study 12123336 — intervention group
Group type: COMPARATOR
Intervention: Filgrastim 5 microg/kg/day
Number of subjects: 100
Study 10561255 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2a (IFNalpha2a) administered three times weekly at 18 x 10(6) IU
Number of subjects: 113
Study 10561255 — intervention group
Group type: COMPARATOR
Intervention: Interleukin‐2 (IL‐2) administered as a continuous intravenous infusion for 5 days (18 x 10(6) IU/m(2)/d)
Number of subjects: 113
Study 10561255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over treatment after failure of IL-2 or IFNalpha2a
Number of subjects: 113
Study 8547958 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IL-2 (4.5 million IU/day, 3 times weekly for 6 months)
Number of subjects: 16
Study 8547958 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous low-dose IL-2
Number of subjects: 16
Study 2275355 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 sec argon laser trabeculoplasty
Number of subjects: 33
Study 2275355 — intervention group
Group type: COMPARATOR
Intervention: 0.2 sec argon laser trabeculoplasty
Number of subjects: 33
Study 485184 — intervention group
Group type: EXPERIMENTAL
Intervention: PUVA plus betamethasone valerate
Number of subjects: 12
Study 485184 — intervention group
Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 12
Study 31401971 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 3395
Study 31401971 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 3395
Study 31401971 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid stenosis
Number of subjects: 3395
Study 31401971 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque
Number of subjects: 3395
Study 29972904 — intervention group
Group type: EXPERIMENTAL
Intervention: 65 μm glycine powder air-polishing (GPAP) therapy
Number of subjects: 21
Study 29972904 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scaling plus polishing paste therapy (Control)
Number of subjects: 21
Study 26153427 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP-guided treatment
Number of subjects: 0
Study 23457213 — intervention group
Group type: EXPERIMENTAL
Intervention: ParkFit programme
Number of subjects: 586
Study 23457213 — intervention group
Group type: COMPARATOR
Intervention: Matched general physiotherapy intervention (Control)
Number of subjects: 586
Study 21464041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin >6.10 μU/ml
Number of subjects: 2903
Study 21464041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin <2.75 μU/ml
Number of subjects: 2903
Study 21464041 — intervention group
Group type: COMPARATOR
Intervention: Insulin 2.75-4.10 μU/ml
Number of subjects: 2903
Study 21464041 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin >6.10 μU/ml with viral load <4.39 log(10) copies/ml
Number of subjects: 2903
Study 21464041 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher insulin levels
Number of subjects: 2903
Study 21464041 — intervention group
Group type: COMPARATOR
Intervention: Glucose or diabetes
Number of subjects: 2903
Study 18262190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 5783
Study 18262190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5783
Study 15616086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar flexion
Number of subjects: 80
Study 15616086 — intervention group
Group type: COMPARATOR
Intervention: Dorsiflexion
Number of subjects: 80
Study 12394544 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPLETE ComfortPLUS (HPMC)
Number of subjects: 64
Study 12394544 — intervention group
Group type: COMPARATOR
Intervention: NO RUB OPTI‐FREE EXPRESS (citrate-based)
Number of subjects: 64
Study 12394544 — intervention group
Group type: EXPERIMENTAL
Intervention: Both solutions
Number of subjects: 64
Study 10193067 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual advice (IA)
Number of subjects: 170
Study 10193067 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 170
Study 7749449 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitor control device (red light to restrict visits, green light to allow visits)
Number of subjects: 60
Study 7749449 — intervention group
Group type: EXPERIMENTAL
Intervention: Visitor control device
Number of subjects: 60
Study 2280167 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored overlay filter (preferred)
Number of subjects: 92
Study 2280167 — intervention group
Group type: COMPARATOR
Intervention: Clear overlay filter
Number of subjects: 92
Study 2280167 — intervention group
Group type: COMPARATOR
Intervention: Different-colored overlay filters
Number of subjects: 92
Study 2280167 — intervention group
Group type: COMPARATOR
Intervention: Nonscotopic children
Number of subjects: 92
Study 380606 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol 200 mg b.i.d.
Number of subjects: 230
Study 380606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 31683021 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretation Bias Modification (IBM-P)
Number of subjects: 48
Study 31683021 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 31127478 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 24–27.9 kg/m2)
Number of subjects: 5163
Study 31127478 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (< 23.9 kg/m2)
Number of subjects: 5163
Study 31127478 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥ 28.0 kg/m2)
Number of subjects: 5163
Study 31127478 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight or Obese
Number of subjects: 5163
Study 28095787 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional functional training as part of the habitual daily routine during short term stays at nursing homes after discharge from hospital.
Number of subjects: 0
Study 25588095 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence skills training (MST)
Number of subjects: 48
Study 25588095 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 48
Study 23449357 — intervention group
Group type: EXPERIMENTAL
Intervention: Mf (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 3 months)
Number of subjects: 855
Study 23449357 — intervention group
Group type: COMPARATOR
Intervention: MFP (MMC 20 mg m(‐2), followed by oral doxifluridine 460‐600 mg m(‐2) per day for 12 months with 6 monthly infusions of 60 mg m(‐2) of cisplatin)
Number of subjects: 855
Study 21150915 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan (TRP) augmentation
Number of subjects: 28
Study 21150915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 18808413 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg biw
Number of subjects: 0
Study 18808413 — intervention group
Group type: COMPARATOR
Intervention: No systemic therapy
Number of subjects: 0
Study 17378197 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial needling at Sanyinjiao (SP 6)
Number of subjects: 120
Study 17378197 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of indometacin entric-coater tablets
Number of subjects: 120
Study 14745611 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled anastomoses (106 anastomoses)
Number of subjects: 201
Study 14745611 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn anastomoses (95 anastomoses)
Number of subjects: 201
Study 11189794 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education and disease management video games
Number of subjects: 2
Study 11189794 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes game
Number of subjects: 2
Study 11189794 — intervention group
Group type: COMPARATOR
Intervention: Entertainment video game (control)
Number of subjects: 2
Study 9894173 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) regimen as studied in ACTG 076
Number of subjects: 0
Study 8040603 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fish oil daily for 3 or 6 months (containing 18% eicosapentaenoic acid and 12% docosahexaenoic acid)
Number of subjects: 15
Study 8040603 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g fish oil daily for 3 or 6 months
Number of subjects: 15
Study 3055324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoretic 100 (atenolol 100 mg; chlorthalidone 25 mg)
Number of subjects: 31
Study 3055324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoretic 50 (atenolol 50 mg; chlorthalidone 25 mg)
Number of subjects: 31
Study 3055324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 3055324 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoretic 100 and Tenoretic 50
Number of subjects: 31
Study 29792052 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT4CBT with brief weekly monitoring
Number of subjects: 137
Study 29792052 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-delivered CBT
Number of subjects: 137
Study 29792052 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 137
Study 28816910 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD group visit model
Number of subjects: 84
Study 24099551 — intervention group
Group type: EXPERIMENTAL
Intervention: OX219 (5.7/1.4mg)
Number of subjects: 100
Study 24099551 — intervention group
Group type: COMPARATOR
Intervention: Suboxone tablets (8/2mg)
Number of subjects: 100
Study 24099551 — intervention group
Group type: COMPARATOR
Intervention: Suboxone films
Number of subjects: 100
Study 24099551 — intervention group
Group type: COMPARATOR
Intervention: Suboxone tablets and films
Number of subjects: 100
Study 24025504 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus capecitabine (TX)
Number of subjects: 92
Study 24025504 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel plus epirubicin (TE)
Number of subjects: 92
Study 21377898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine (6 μg hemagglutinin per strain)
Number of subjects: 85
Study 21377898 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccine (15 μg hemagglutinin per strain)
Number of subjects: 85
Study 21377898 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal vaccine
Number of subjects: 85
Study 21377898 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccine
Number of subjects: 85
Study 18163423 — intervention group
Group type: EXPERIMENTAL
Intervention: UMTS at 2140 MHz
Number of subjects: 80
Study 18163423 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 80
Study 18163423 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined data from adolescents and adults
Number of subjects: 80
Study 14999442 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care group (SOC) - all CVCs were changed as planned
Number of subjects: 64
Study 14999442 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting group (WW) - CVCs changed when bacteremia was confirmed or hemodynamic instability occurred
Number of subjects: 64
Study 14999442 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-of-care group (SOC)
Number of subjects: 64
Study 14999442 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting group (WW)
Number of subjects: 64
Study 14999442 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care group (SOC) and Watchful waiting group (WW)
Number of subjects: 64
Study 11372588 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once daily for 4 days
Number of subjects: 12
Study 11372588 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo once daily for 4 days
Number of subjects: 12
Study 9589673 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH treatment
Number of subjects: 0
Study 8303743 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation (younger patients)
Number of subjects: 245
Study 8303743 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation (older patients)
Number of subjects: 245
Study 8303743 — intervention group
Group type: COMPARATOR
Intervention: General wards (younger patients)
Number of subjects: 245
Study 8303743 — intervention group
Group type: COMPARATOR
Intervention: General wards (older patients)
Number of subjects: 245
Study 2968185 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (FEN) 75 micrograms.kg‐1
Number of subjects: 96
Study 2968185 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (SUF) 15 micrograms.kg‐1
Number of subjects: 96
Study 2968185 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (ALF) 125 micrograms.kg‐1
Number of subjects: 96
Study 30336863 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal handshake technique
Number of subjects: 45
Study 30336863 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation
Number of subjects: 45
Study 27475670 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately hypofractionated radiation therapy (MHRT) - 62 Gy in 20 fractions over 5 weeks
Number of subjects: 168
Study 27475670 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionated radiation therapy (CFRT) - 80 Gy in 40 fractions over 8 weeks
Number of subjects: 168
Study 25431225 — intervention group
Group type: EXPERIMENTAL
Intervention: Qishenyiqi Dripping Pills
Number of subjects: 144
Study 25431225 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound Danshen Dripping Pills
Number of subjects: 144
Study 22406102 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 42
Study 22406102 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 42
Study 20520854 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage Migration Inhibitory Factor (MIF) as a biomarker
Number of subjects: 0
Study 20520854 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional promoter polymorphisms in the MIF gene
Number of subjects: 0
Study 18573168 — intervention group
Group type: EXPERIMENTAL
Intervention: Modules with complex cases
Number of subjects: 124
Study 18573168 — intervention group
Group type: COMPARATOR
Intervention: Modules without complex cases
Number of subjects: 124
Study 16925236 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 59
Study 16925236 — intervention group
Group type: COMPARATOR
Intervention: Jejunoileal bypass
Number of subjects: 59
Study 11818981 — intervention group
Group type: EXPERIMENTAL
Intervention: Paico juice (1 ml/Kg for <10 Kg, 2 ml/Kg for >10 Kg, one dose before breakfast for three consecutive days)
Number of subjects: 60
Study 11818981 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg for >5 years, 200 mg for <5 years, single dose)
Number of subjects: 60
Study 11818981 — intervention group
Group type: EXPERIMENTAL
Intervention: Paico juice
Number of subjects: 60
Study 11818981 — intervention group
Group type: COMPARATOR
Intervention: Paico and Albendazole
Number of subjects: 60
Study 10194990 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl infusion (1.1 micrograms/kg/h for 75 hours)
Number of subjects: 55
Study 10194990 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated infants)
Number of subjects: 55
Study 7917782 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal site perfusion of paracetamol
Number of subjects: 4
Study 7917782 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal site perfusion of paracetamol
Number of subjects: 4
Study 3207491 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil cardioplegia
Number of subjects: 16
Study 3207491 — intervention group
Group type: COMPARATOR
Intervention: Cold cardioplegia without verapamil
Number of subjects: 16
Study 31547675 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean meal (SBM)
Number of subjects: 288
Study 31547675 — intervention group
Group type: EXPERIMENTAL
Intervention: High digestibility crude protein (DCP) level (17.2%)
Number of subjects: 288
Study 31547675 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed meal (RSM)
Number of subjects: 288
Study 31547675 — intervention group
Group type: COMPARATOR
Intervention: Rapeseed meal (RSM) and maize gluten (MG)
Number of subjects: 288
Study 30782695 — intervention group
Group type: EXPERIMENTAL
Intervention: New mobile health (mHealth) screen
Number of subjects: 1500
Study 30782695 — intervention group
Group type: COMPARATOR
Intervention: Current school hearing screen
Number of subjects: 1500
Study 29211951 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.6% edathamil gel (Livionex® Dental Gel)
Number of subjects: 9
Study 29211951 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste
Number of subjects: 9
Study 25266794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 L hydroxyethyl starch 6% 130/0.42 (Group T)
Number of subjects: 32
Study 25266794 — intervention group
Group type: COMPARATOR
Intervention: 1 L Ringer's lactate (Group R/L)
Number of subjects: 32